MMCM
CPRX

Murphy & Mullick Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Murphy & Mullick Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.5K Hold
1,150
– – 0.02% 359
2025
Q4 		$26.8K Hold
1,150
– – 0.02% 369
2025
Q3 		$24.1K Hold
1,150
– – 0.02% 368
2025
Q2 		$25K Hold
1,150
– – 0.02% 351
2025
Q1 		$27.9K Hold
1,150
– – 0.03% 327
2024
Q4 		$24K Buy
+1,150
New +$24.7K 0.02% 336

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Murphy & Mullick Capital Management's CPRX Position: Q1 2026 in Review

Murphy & Mullick Capital Management held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 1,150 shares worth $28.5K. The position accounts for 0.02% of the portfolio, ranked #359.

Murphy & Mullick Capital Management first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Murphy & Mullick Capital Management held 1,150 shares of Catalyst Pharmaceutical worth $28.5K as of Q1 2026.
  • Murphy & Mullick Capital Management left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up 0.02% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #359 holding.
  • Murphy & Mullick Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.